QQ客服 官方微博 反馈留言

	A novel lead compound CM-118 Antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers
	Meng, Lanfang; Shu, Mengjun; Chen, Yaqing; Yang, Dexiao; He, Qun; Zhao, Hui; Feng, Zhiyong; Liang, Chris; Yu, Ker
刊名	CANCER BIOLOGY & THERAPY
	2014
卷号	15期号:6
关键词	c-Met ALK EGFR mTOR targeted cancer therapy combination therapy
ISSN号	1538-4047
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4882838
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Meng, Lanfang,Shu, Mengjun,Chen, Yaqing,et al. A novel lead compound CM-118 Antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers[J]. CANCER BIOLOGY & THERAPY,2014,15(6).
APA	Meng, Lanfang.,Shu, Mengjun.,Chen, Yaqing.,Yang, Dexiao.,He, Qun.,...&Yu, Ker.(2014).A novel lead compound CM-118 Antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.CANCER BIOLOGY & THERAPY,15(6).
MLA	Meng, Lanfang,et al."A novel lead compound CM-118 Antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers".CANCER BIOLOGY & THERAPY 15.6(2014).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。